2021 – Page 32 – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2021-01-20

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

SARS-CoV-2 501Y.V2, a novel lineage of the coronavirus causing COVID-19, contains multiple mutations within two immunodominant domains of the spike protein. In a paper recently published on https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1.full.pdf it’s shown that this lineage exhibits complete escape from three classes of therapeutically relevant monoclonal antibodies. Furthermore 501Y.V2 shows substantial or complete escape from neutralizing antibodies in

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-20

B.1.1.7 SARS-CoV-2 (UK) and other variants description

At the heart of each coronavirus is its genome, a twisted strand of nearly 30,000 “letters” of RNA. These genetic instructions force infected human cells to assemble up to 29 kinds of proteins that help the coronavirus multiply and spread. As viruses replicate, small copying errors known as mutations naturally arise in their genomes. A lineage of coronaviruses will

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-19

Update on new SARS-CoV-2 emerging variants (UK, South Africa, Brazil and California)

What do we know about the new variant emerging from Brazil? This variant, known as P.1 or VOC202101/02 in the UK, was first detected in travellers from Brazil who arrived in Japan in January 2021. It involves 17 unique amino acid changes, three deletions, four synonymous mutations, and one 4nt insertion. It has several mutations

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-19

Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug

Research conducted by the University of Bari in collaboration with the Campus Bio-Medico University of Rome The studies carried out by the research team of the University of Bari in collaboration with the Campus Bio-Medico University of Rome, formed by Luigi Leonardo Palese, Anna Maria Sardanelli, and Camilla Isgrò of the Department of Basic Medical

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-18

Could Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise Hopes

A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both therapies work by switching on a gene that promotes production of fetal hemoglobin, said Dr. Lewis Hsu, chief medical officer of the Sickle Cell Disease Association

No Comments InGENE THERAPY RARE DISEASES

PIER MARIA FORNASARI
2021-01-17

Saliva tests may be just as good as nasopharingeal swabs for COVID-19

COVID-19 tests that use patients’ saliva to screen for the virus are just as effective as those that use swabs collected from the nose and throat, an analysis published by JAMA Internal Medicine found. Saliva-based tests correctly identified those infected with the new coronavirus 83% of the time, while nose-throat swab tests were 85% accurate, the review of

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-16

For CDC the more contagious SARS-CoV-2 B.1.1.7 variant may soon be the U.S.’s dominant strain

On December 14, 2020, the United Kingdom reported a SARS-CoV-2 variant of concern (VOC), lineage B.1.1.7, also referred to as VOC 202012/01 or 20I/501Y.V1.* The B.1.1.7 variant is estimated to have emerged in September 2020 and has quickly become the dominant circulating SARS-CoV-2 variant in England (1). B.1.1.7 has been detected in over 30 countries,

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-16

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19, due to no convincing evidence of the effect on clinical outcomes.

The RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19. Since May 2020, the RECOVERY trial has included a randomised comparison of convalescent plasma vs. usual care alone. Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no

No Comments InCovid-19

PIER MARIA FORNASARI
2021-01-15

The Future of CAR T cells in multiple myeloma

Despite the significant improvement in survival outcomes of multiple myeloma (MM) over the past decade, it remains an incurable disease. Patients with triple-class refractory MM have limited treatment options and a dismal prognosis. Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen has transformed the treatment armamentarium of relapsed/refractory MM (RRMM), with unprecedented overall

No Comments InCAR-T

PIER MARIA FORNASARI
2021-01-12

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19: observational study published in Gut BMJ.

Imbalances in type and volume of bacteria may also be implicated in ‘long COVID’ The variety and volume of bacteria in the gut, known as the microbiome, may influence the severity of COVID-19 as well as the magnitude of the immune system response to the infection, suggests research published online in the journal Gut. Imbalances in

No Comments InCovid-19

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Archives: 2021-01-20

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma

B.1.1.7 SARS-CoV-2 (UK) and other variants description

Update on new SARS-CoV-2 emerging variants (UK, South Africa, Brazil and California)

Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug

Could Gene Therapy Cure Sickle Cell Disease? Two New Studies Raise Hopes

Saliva tests may be just as good as nasopharingeal swabs for COVID-19

For CDC the more contagious SARS-CoV-2 B.1.1.7 variant may soon be the U.S.’s dominant strain

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19, due to no convincing evidence of the effect on clinical outcomes.

The Future of CAR T cells in multiple myeloma

Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19: observational study published in Gut BMJ.